Source disclosure: January 28, 2026
CellSource Co., Ltd. [4880.T]
TOKYO, Jan 28 (Pulse News Wire) – Cellsource CO.,LTD. (4880.T) announced today that its board of directors has decided to apply for a market classification change to the Tokyo Stock Exchange Standard Market.
The decision was made due to the company's inability to meet the maintenance criteria of the Prime Market, which requires a circulating stock market value of ¥10.00 billion or more. Despite previously moving to the Prime Market in October 2023 to promote industrialization of regenerative medicine-related businesses, the company fell short of the criteria in the fiscal year ending October 2025 due to poor performance. As of October 31, 2025, according to the company’s estimates, it meets all the listing review standards for the Standard Market, including shareholder count, circulating share volume, circulating market value, and circulation ratio.
However, the approval date remains undetermined, and there is uncertainty whether the application will be accepted by the Tokyo Stock Exchange. Should the necessary conditions not be met, the request could be denied. Going forward, the company plans to focus on enhancing long-term corporate value within the Standard Market.
Any further developments related to this matter will be disclosed promptly.
AI-translated content. 🟢 Confidence: High See terms • Original filing